United Therapeutics Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
February 21, 2024 at 06:00 am EST
Share
United Therapeutics Corporation reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was USD 614.7 million compared to USD 491.5 million a year ago. Net income was USD 217.1 million compared to USD 132.1 million a year ago. Basic earnings per share from continuing operations was USD 4.62 compared to USD 2.88 a year ago. Diluted earnings per share from continuing operations was USD 4.36 compared to USD 2.67 a year ago.
For the full year, the company reported sales was USD 2,327.5 million compared to USD 1,936.3 million a year ago. Net income was USD 984.8 million compared to USD 727.3 million a year ago. Basic earnings per share from continuing operations was USD 21.04 compared to USD 15.98 a year ago. Diluted earnings per share from continuing operations was USD 19.81 compared to USD 15 a year ago.
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKindâs Afrezza (insulin human) Inhalation Powder.
UNITED THERAPEUTICS CORPORATION 
